CME

Faculty: Diana V. Do, MD

Faculty: David Boyer, MD

This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

Faculty: Marion Munk, MD, Ph.D

Faculty: Diana V. Do, MD

This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

Faculty: David Boyer, MD

Faculty: Marion Munk, MD, Ph.D

This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

Host: Jaime Almandoz, MD, MBA, MRCPI, FTOS, DABOM

Guest: Daniel C. Butler, MD

Guest: Benjamin Ungar, MD

On-demand webcast of expert faculty presentation on the key connection between psoriasis and obesity, including comprehensive treatment strategies that consider outcomes improvement for both diseases.

Host: Stella Lee, MD

Guest: Katie Buchheit, MD

Guest: Michael E. Wechsler, MD, MMSc

Chronic rhinosinusitis with nasal polyps (CRSwNP) presents a large burden on more than 3 million patients with the conditions — especially when intertwined with asthma and allergy. Join our discussion between patients with CRSwNP and leading experts in ENT, allergy, and pulmonary medicine as they:

• Breakdown how to recognize key inflammatory patterns.
• Discuss the burden of illness and goals of treatment
• Interpret clinical trial data on biologic treatments.
• Apply a collaborative care approach to improve patient outcomes.

Watch now to explore cases with patient panelists, expert perspectives, and evidence-based strategies for managing CRSwNP in multidisciplinary settings.

Host: Stephen Nicholls, FRACP, FACC, FESC, FAHA

This program is intended for health care professionals only.

Dr. Stephen Nicholls reveals new data on obicetrapib that are showing promise in reducing cardiovascular events.

Faculty: Durga Borkar, MD, MMCi

Faculty: Veeral Sheth, MD, MBA, FASRS, FACS

Need to catch up on the latest data surrounding next-generation retinal treatments? Drs. Veeral Sheth and Durga Borkar walk through the most recent efficacy and safety data around faricimab, aflibercept 8 mg, and the PDS with ranibizumab. They also review the latest insights on the use of these treatments in real-world practice.

Faculty: Durga Borkar, MD, MMCi

Faculty: Veeral Sheth, MD, MBA, FASRS, FACS

Wondering how your practice’s use of next-generation retinal agents compares to the experts? Join Dr. Durga Borkar and Dr. Veeral Sheth as they discuss how they are using next-generation agents to free their patients from frequent office visits.

Host: Kevin J Harrington, PhD, FRCP, FRCR, FRSB

Host: Christophe Le Tourneau, MD, PhD

Join our experts as they examine the integration of perioperative immune checkpoint inhibitors (ICIs) in the management of resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC). Drs. Le Tourneau and Harrington discuss unmet needs and limitations of current treatment and review data from trials supporting the use of perioperative ICIs, emphasizing their event-free survival and pathologic response outcomes. The conversation also addresses multidisciplinary coordination and considerations for managing immune-related adverse events. Variations in treatment guidelines, access, and clinical practice between the US, Europe, and other regions are explored to contextualize the challenges of global implementation and provide strategies for practitioners to improve care.

Host: Marwan Sabbagh, MD, FAAN

Guest: Alireza Atri, MD, PhD

Guest: Christoph U. Correll, MD

Neuropsychiatric symptoms (NPS) associated with Alzheimer’s disease (AD), such as psychosis and agitation, affect up to 50% of individuals with AD yet remain underdiagnosed and undertreated in clinical practice. These symptoms accelerate cognitive decline, increase mortality risk, and substantially worsen patient and caregiver quality of life. This broadcast replay will provide a practical and engaging discussion of the underlying pathophysiology of NPS associated with AD, the limitations of off-label antipsychotic use, and emerging therapeutic agents targeting NPS associated with AD.